Enzene Sees Tariff Exemptions For India, Front-Ends US Capacity

Enzene’s CEO Himanshu Gadgil anticipates exemptions for Indian products from US tariffs expected to be imposed on pharmaceuticals. In an interview ahead of the US Vice Premier’s India visit, he also talks about front-loading capacity at Enzene’s US plant and a change in its biosimilars strategy

Source : https://insights.citeline.com/

Date: 22/04/2025

Enzene Sees Tariff Exemptions For India, Front-Ends US Capacity

The most advanced innovation is only one step away.

From discovery to commercial supply, an Enzene partnership brings a new way of thinking about biologics.

Let’s discuss your challenge or project.